TORONTO and BOULDER, Colo., April 12, 2019 (GLOBE NEWSWIRE) — Mandara Pharma, a global market leader in naturally occurring cannabidiol (“CBD”) and cannabis-based pharmaceutical research, today announced a strategic partnership with BoomRx, a leading innovator in the CBD marketplace. As part of the strategic partnership, BoomRx will change its corporate name to MandaraRx to help drive brand value in the CBD market.
The alliance leverages both Mandara Pharma’s extensive capabilities in therapy-driven cannabinoid scientific research as well as BoomRx’s capacity to develop innovative products and broad team of market-driven certified wellness coaches to create a new industry standard for quality and efficacy.
“We are thrilled to develop a strategic partnership with BoomRx,” said Dr. Jeremy Desai, Mandara Pharma’s President and CEO. “Their focus on innovation, world-class service and their network of certified wellness coaches are a perfect fit for us as we continue to evolve and plan for global expansion. As one of the industry’s most innovative companies, we will benefit greatly from their sales and marketing expertise and tremendous leadership team.”
“During 2019, our evolution will include developing and launching innovative new products to positively impact the future landscape of the industry,” said Wallace Reams, BoomRx’s Co-Founder and Chief Product Officer. “Our goal is to design new technology-driven products that consumers can trust. Given the void of science-based CBD products within the category, there could not be a more opportune time to develop a strategic partnership leveraging the significant scientific expertise of Mandara Pharma.”
The vision for MandaraRx, previously known as BoomRx, is unlike anything the CBD market has seen: an efficacy-proven, technologically advanced, integrated ecosystem, including innovative products, world-class service and a national network of certified wellness coaches. With an Executive team of leaders experienced in building innovative products and rapid-growth companies, MandaraRx is well positioned to be the most innovative company in the CBD market.
About Mandara Pharma
Mandara Pharma, Inc. (Mandara) is a Canadian pharmaceutical cannabis company holding licenses in Colombia for the cultivation (both psychoactive and non-psychoactive cannabis plants), extraction, transformation and export. Mandara has also obtained a license in Spain to cultivate CBD clones containing less than 0.2% THC from EU-registered seeds. Led by President & CEO Dr. Jeremy B. Desai, an internationally renowned pharmaceutical executive with over 30 years of experience, Mandara has built a top-class management team comprising of renowned cultivators who have developed a rich genetics library (over 200 strains registered in Colombia), including land races and a number of unique strains developed by our cultivators and breeders. Over and above the 2.5 million square feet of cultivation capacity, Mandara has developed a unique “Social Entrepreneurship” program in Colombia to assist the indigenous, conflicted communities in becoming part of the legalized cannabis industry and has plans to replicate this program in other Latin American and South American countries suffering from similar social challenges.
“Mandara Pharma is committed to bring to the world, natures nurturing plant for the betterment of mankind”
For additional questions or information, please contact:
David Hurley | Chief Business Development Officer, MandaraRx 808.497.7771 (mobile) firstname.lastname@example.org Priscilla Agoncillo | Chief Business Officer, Mandara Pharma 949.275.2115 (mobile) email@example.com